In this article, we will look at the 8 Healthcare Stocks Insiders Are Buying.
Insider buying tends to draw attention because insiders know their companies best. That is especially true in the healthcare sector, where company stock moves can be driven by regulatory headlines, clinical data, and shifting sentiment. In that kind of market, insider purchases tend to stand out because they can suggest that the management sees more value in the business than the market is currently giving it credit for.
The institutional case lines up with that view. J.P. Morgan Asset Management’s Undiscovered Managers Behavioral Value Fund says its behavioral value strategy looks for “significant insider buying” alongside “attractive fundamentals.” On the sector side, Franklin Templeton says healthcare offers an “attractive entry point,” supported by “positive earnings revisions” and “robust innovation in drug pipelines.” Capital Group makes a similar argument, pointing to a gap between “underlying business strength” and “appealing stock valuations.” Insider buying matters more when it appears in a part of the market that may already be undervalued on its own merits.
Against this backdrop, healthcare stocks seeing insider purchases deserve a closer look. We will now look at the 8 Healthcare Stocks Insiders Are Buying.
Our Methodology
We used the Finviz screener to identify healthcare stocks with a significant increase in insider ownership over the last six months. We then limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
8. Kodiak Sciences Inc. (NASDAQ:KOD)
On April 1, 2026, Kodiak Sciences Inc. (NASDAQ:KOD) reported Q4 EPS of ($1.05) compared to (84c) last year. Victor Perlroth, M.D., Chief Executive Officer, said momentum is building, citing “positive Phase 3 topline results” from the GLOW2 study and progress across late-stage and pipeline programs supporting the company’s long-term strategy.
On March 27, 2026, UBS raised its price target on Kodiak Sciences Inc. to $80 from $50 previously and maintained a Buy rating on the shares. UBS said it is bullish on both tarcocimab VEGF and IL6.
Similarly, H.C. Jefferies raised its price target on Kodiak Sciences Inc. to $56 from $39 previously and maintained a Buy rating on the shares, noting GLOW2 results showed improved safety and efficacy versus GLOW1, with the reformulation seen as a safety improvement and potential driver of durability in the Phase III DAYBREAK study, while also supporting earlier Biologics License Application timing.
Kodiak Sciences Inc. develops therapies for retinal diseases.
7. Wave Life Sciences Ltd. (NASDAQ:WVE)
On April 7, 2026, RBC Capital analyst Luca Issi lowered the price target on Wave Life Sciences Ltd. (NASDAQ:WVE) to $15 from $27 and maintained an Outperform rating as part of a Q1 biotech preview. Luca Issi said seasonal headwinds around gross-to-net, reimbursement resets, and fewer selling days may be exacerbated by weather impacts, particularly for launching and in-clinic products, while noting that a return of M&A activity and clarity on tariff and Most Favored Nation drug pricing could help offset broader macro pressures.
On March 27, 2026, BofA lowered its price target on Wave Life Sciences to $21 from $38 and maintained a Buy rating following updated Phase 1 data for WVE-007 in obesity. BofA said additional data is needed to support the monotherapy case, but noted potential opportunities in higher BMI patients and in combination or maintenance settings.
On March 26, 2026, Wave Life Sciences reported new Phase 1 INLIGHT trial data for WVE-007, showing that a single 240 mg dose led to reductions in visceral fat, waist circumference, and body weight, while preserving muscle, with up to 88% reduction in Activin E sustained for at least seven months. The treatment was generally safe and well-tolerated, with no serious adverse events, and additional cohorts showed similar trends, supporting plans to begin a Phase 2a multidose study in the second quarter of 2026 and further trials evaluating monotherapy and combination approaches.
Wave Life Sciences Ltd. develops RNA-based therapeutics.
6. Biohaven Ltd. (NYSE:BHVN)
On April 2, 2026, Citi analyst Samantha Semenkow raised the price target on Biohaven Ltd. (NYSE:BHVN) to $17 from $14 and maintained a Buy rating. Samantha Semenkow said the firm sees attractive risk/reward at current levels ahead of 2026 catalysts, noting recent competitor data in focal epilepsy are supportive of Biohaven’s Phase 3 opakalim trial expected to read out in the second half of 2026.
On March 19, 2026, Biohaven Ltd. announced completion of enrollment in a Phase 2 proof-of-concept study for taldefgrobep alfa, a myostatin-activin pathway inhibitor aimed at weight loss in obesity, with topline data expected in the second half of 2026.
Earlier in March, Goldman Sachs raised its price target on Biohaven Ltd. to $27 from $24 and maintained a Buy rating, citing positive Phase 3 results from Xenon’s azetukalner in focal onset seizures and viewing the data as supportive for the broader Kv7 class, including Biohaven’s opakalim.
Biohaven Ltd. develops therapies across immunology, neuroscience, and oncology.
5. Aktis Oncology, Inc. (NASDAQ:AKTS)
On March 31, 2026, H.C. Wainwright analyst Robert Burns raised the firm’s price target on Aktis Oncology, Inc. (NASDAQ:AKTS) to $33 from $30 previously and maintained a Buy rating on the shares. Robert Burns has said that the company’s pipeline is expected to advance and expand over the next twelve months.
On March 30, 2026, Aktis Oncology, Inc. announced the FDA clearance of investigational new drug applications to begin a Phase 1b trial for AKY-25191, a miniprotein radioconjugate targeting B7-H3 across multiple solid tumors, including prostate and lung cancers.
Aktis Oncology, Inc. said that AKY-2519 is its second clinical-stage miniprotein radioconjugate, while its lead program, AKY-1189, targeting Nectin-4, is already enrolling in a Phase 1b study, with both designed to deliver actinium-225 to tumor sites.
Aktis Oncology, Inc. develops radiopharmaceutical therapies for solid tumors.
4. Veradermics, Incorporated (NYSE:MANE)
On March 30, 2026, Veradermics, Incorporated (NYSE:MANE) reported a Q4 net loss of $21.8M and ended the year with $141.9M in cash, cash equivalents, and marketable securities. CEO Reid Waldman said 2025 was a “landmark year,” highlighting progress in Phase 3 development of VDPHL01 and the company’s IPO, while noting expectations for two Phase 3 readouts in men, continued progress toward an NDA submission, and advancement of a Phase 3 trial for female pattern hair loss.
Earlier in March, Cantor Fitzgerald analyst Prakhar Agrawal initiated coverage on Veradermics, Incorporated with an Overweight rating, noting the company’s focus on dermatology and its use of “validated biology” of minoxidil with optimized pharmacokinetics to improve efficacy and safety.
Similarly, Leerink initiated coverage on Veradermics, Incorporated with an Outperform rating and a $75 price target, highlighting the large market for hair loss treatments and positioning VDPHL01 as a potential best-in-class oral therapy for both men and women, supported by a hybrid marketing strategy combining telehealth and direct access.
Veradermics, Incorporated develops therapies for dermatologic and aesthetic conditions.
3. Sonida Senior Living, Inc. (NYSE:SNDA)
On April 7, 2026, Morgan Stanley raised the price target on Sonida Senior Living, Inc. (NYSE:SNDA) to $31 from $28 previously and maintained an Equal Weight rating on the shares. Morgan Stanley has said that the update reflects revised risk/reward following Q4 earnings and 2026 guidance, noting that Sonida Senior Living, Inc. is in the early stages of a turnaround and could benefit from favorable senior housing demographics and limited supply.
On March 27, 2026, RBC Capital Markets initiated coverage on Sonida Senior Living, Inc. with an Outperform rating and a $39 price target on the shares. RBC Capital has said that the acquisition of SNL Healthcare Properties is “transformative,” adding scale, earnings accretion, and reduced leverage, while positioning Sonida Senior Living, Inc. to benefit from demand driven by aging demographics in a supply-constrained environment.
Sonida Senior Living, Inc. owns and operates senior housing communities in the United States.
2. Phreesia, Inc. (NYSE:PHR)
On April 5, 2026, Wells Fargo lowered the price target on Phreesia, Inc. (NYSE:PHR) to $15 from $25 and maintained an Overweight rating. Wells Fargo said fiscal 2027 revenue guidance “decelerated sharply,” largely driven by the Network segment, citing valuation compression and slower growth, while noting recent Network channel checks were constructive.
On April 1, 2026, Citizens downgraded Phreesia to Market Perform from Outperform without a price target. Citizens said the updated fiscal 2027 revenue outlook was disappointing and raised concerns around the company’s ecosystem thesis, noting growth appears to be “sputtering out” in its largest subscription and related services segment.
On March 30, 2026, Phreesia reported Q4 adjusted EBITDA of $29.4M compared to $16.4M last year, with revenue of $127.1M versus the $126.6M consensus estimate. CEO Chaim Indig said the company achieved “critical financial milestones,” including positive GAAP net income of $2.3M and exceeding $100M in adjusted EBITDA and $50M in free cash flow for fiscal 2026.
Phreesia, Inc. provides SaaS-based software and payment solutions for the healthcare industry.
1. MapLight Therapeutics, Inc. (NASDAQ:MPLT)
On April 8, 2026, Needham initiated coverage of MapLight Therapeutics, Inc. (NASDAQ:MPLT) with a Buy rating and a $37 price target. Needham said the muscarinic class could be “disruptive” across multiple indications, including schizophrenia and Alzheimer’s disease psychosis, and noted ML-007C-MA may be “differentiated” from Cobenfy on tolerability and convenience, with potential to reach $1.5B in sales by 2035.
On April 7, 2026, TD Cowen initiated coverage of MapLight Therapeutics with a Buy rating, highlighting its pipeline targeting central nervous system and neuropsychiatric conditions. TD Cowen said the lead asset ML-007C-MA is positioned to improve on Cobenfy’s profile in schizophrenia, with a Phase II readout expected in Q3, and views the shares as undervalued based on this opportunity.
Last month, Canaccord initiated coverage of MapLight Therapeutics with a Buy rating and a $35 price target. Canaccord said the company’s focus on novel CNS therapeutics supports its schizophrenia opportunity and recommends buying the stock ahead of Phase 2 data for ML-007C-MA expected in Q3.
MapLight Therapeutics, Inc. develops therapies for central nervous system disorders.
READ NEXT: 10 Best Stocks That Beat Earnings Estimates and 10 Best 52-Week Low NASDAQ Stocks to Buy Now.
